Progyny, Inc. (NASDAQ:PGNY) Receives $28.80 Average Target Price from Analysts

Shares of Progyny, Inc. (NASDAQ:PGNY) have received an average recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $29.0909.

Several equities research analysts have weighed in on the stock. Jefferies Financial Group reiterated a “buy” rating and issued a $30.00 target price on shares of Progyny in a report on Friday. Citigroup upgraded shares of Progyny to an “outperform” rating in a research report on Tuesday, January 20th. Truist Financial reduced their target price on Progyny from $34.00 to $28.00 and set a “buy” rating on the stock in a report on Monday, March 2nd. JPMorgan Chase & Co. set a $35.00 target price on Progyny in a research note on Wednesday, January 21st. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Progyny in a report on Monday, December 29th.

Progyny Trading Up 3.9%

Shares of PGNY opened at $18.31 on Thursday. The stock has a market cap of $1.50 billion, a P/E ratio of 28.17, a price-to-earnings-growth ratio of 1.24 and a beta of 1.01. Progyny has a 1 year low of $16.75 and a 1 year high of $28.75. The stock’s 50-day moving average price is $23.09 and its two-hundred day moving average price is $22.92.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. Progyny had a net margin of 4.54% and a return on equity of 11.37%. The business had revenue of $318.40 million for the quarter, compared to the consensus estimate of $314.26 million. During the same period last year, the company posted $0.42 EPS. Progyny’s revenue for the quarter was up 6.7% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. As a group, equities analysts forecast that Progyny will post 0.6 EPS for the current year.

Insider Transactions at Progyny

In related news, EVP Allison Swartz sold 4,657 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $17.40, for a total transaction of $81,031.80. Following the completion of the sale, the executive vice president directly owned 89,879 shares of the company’s stock, valued at approximately $1,563,894.60. This represents a 4.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last three months, insiders sold 7,455 shares of company stock worth $129,515. 9.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada raised its holdings in shares of Progyny by 384.8% during the first quarter. Royal Bank of Canada now owns 13,027 shares of the company’s stock worth $291,000 after acquiring an additional 10,340 shares during the period. Amundi increased its holdings in Progyny by 103.8% during the 1st quarter. Amundi now owns 11,419 shares of the company’s stock worth $264,000 after purchasing an additional 5,817 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Progyny by 6.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company’s stock valued at $5,630,000 after purchasing an additional 14,297 shares during the period. Cetera Trust Company N.A raised its stake in shares of Progyny by 303.1% in the 2nd quarter. Cetera Trust Company N.A now owns 1,310 shares of the company’s stock valued at $29,000 after purchasing an additional 985 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Progyny by 357.9% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 116,138 shares of the company’s stock valued at $2,555,000 after purchasing an additional 90,775 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.